Haroutunian V, Kanof P D, Tsuboyama G, Davis K L
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029.
Brain Res. 1990 Jan 22;507(2):261-6. doi: 10.1016/0006-8993(90)90280-o.
The effects of combined lesions of forebrain cholinergic and noradrenergic systems on memory and responsivity to the memory enhancing effects of cholinomimetics were investigated in rats. Forebrain noradrenergic deficits produced by the injection of 6-hydroxydopamine into the ascending noradrenergic bundle (ANB) blocked the ability of cholinomimetics such as physostigmine and oxotremorine to enhance retention test performance in nucleus basalis of Meynert lesioned rats. Low doses of the noradrenergic receptor agonist clonidine, when administered in conjunction with cholinomimetics reversed this blockade. These results suggest that combined cholinergic/noradrenergic therapy may be of value in the treatment of some Alzheimer's disease patients.
在大鼠中研究了前脑胆碱能和去甲肾上腺素能系统联合损伤对记忆以及对拟胆碱药记忆增强作用反应性的影响。通过向升支去甲肾上腺素能束（ANB）注射6-羟基多巴胺产生的前脑去甲肾上腺素能缺陷，阻断了诸如毒扁豆碱和氧化震颤素等拟胆碱药增强Meynert基底核损伤大鼠记忆保持测试表现的能力。低剂量的去甲肾上腺素能受体激动剂可乐定与拟胆碱药联合给药时可逆转这种阻断作用。这些结果表明，胆碱能/去甲肾上腺素能联合疗法可能对某些阿尔茨海默病患者的治疗有价值。
